In the latest trading session,, 75.43 million Evogene Ltd (NASDAQ:EVGN) shares changed hands as the company’s beta touched 1.55. With the company’s most recent per share price at $1.83 changing hands around $0.7 or 61.50% at last look, the market valuation stands at $12.18M. EVGN’s current price is a discount, trading about -292.9% off its 52-week high of $7.19. The share price had its 52-week low at $0.95, which suggests the last value was 48.09% up since then. When we look at Evogene Ltd’s average trading volume, we note the 10-day average is 32670.0 shares, with the 3-month average coming to 368.46K.
Analysts gave the Evogene Ltd (EVGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 1 recommended EVGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Evogene Ltd’s EPS for the current quarter is expected to be -0.63.
Evogene Ltd (NASDAQ:EVGN) trade information
Instantly EVGN is in green as seen in intraday trades today. With action 64.41%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -2.41%, with the 5-day performance at 64.41% in the green. However, in the 30-day time frame, Evogene Ltd (NASDAQ:EVGN) is 61.15% up. Looking at the short shares, we see there were 0.18 million shares sold at short interest cover period of 0.18 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.5, meaning bulls need an upside of 47.71% from its recent market value. According to analyst projections, EVGN’s forecast low is 3.5 with 3.5 as the target high. To hit the forecast high, the stock’s price needs a -91.26% plunge from its current level, while the stock would need to soar -91.26% for it to hit the projected low.
Evogene Ltd (EVGN) estimates and forecasts
Year-over-year growth is forecast to reach -23.82% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 930k. 2 analysts are of the opinion that Evogene Ltd’s revenue for the current quarter will be 905k. The company’s revenue for the corresponding quarters a year ago was 914k and 1.8M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1.75%. The estimates for the next quarter sales put growth at -49.61%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 16.27%. The 2025 estimates are for Evogene Ltd earnings to increase by 23.53%, but the outlook for the next 5-year period is at 29.80% per year.
EVGN Dividends
Evogene Ltd is expected to release its next quarterly earnings report on 2025-Mar-05.
Evogene Ltd (NASDAQ:EVGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.26% of Evogene Ltd shares while 6.46% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.55%. There are 6.46% institutions holding the Evogene Ltd stock share, with SILVERARC CAPITAL MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 6.0837% of the shares, roughly 3.08 million EVGN shares worth $2.0 million.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 0.4315% or 0.22 million shares worth $0.14 million as of 2024-06-30.
With 5.9 shares estimated at $11034.0 under it, the former controlled 0.01% of total outstanding shares.
